Sanofi (EURONEXT: SAN and NYSE: SNY) announced today, at the
71st Scientific American Diabetes Association Sessions
2011, the results of three studies showing that people with
diabetes using Sanofi insulins Lantus® and/or
Apidra® with the insulin delivery device
SoloSTAR® experienced greater treatment satisfaction,
better quality of life and lower fear of hypoglycemia vs those
using a premixed insulin product.

The goal of the first study[1], involving
586 patients with uncontrolled type 2 diabetes on oral agents, was
to evaluate any changes in physical and psychological well-being,
diabetes-related symptoms, and patient satisfaction with
diabetes-related care and treatment over the study period and from
baseline to endpoint.

It showed that, compared with those on twice-daily premixed
70/30 insulin aspart (premix), patients on the combination of
Lantus®- and Apidra®-based regimens
experienced better quality of life as measured by the Diabetes
Quality of Life (DQoL) questionnaire, which evaluates personal
perception of improvements as a result of treatment:

Compared to the glargine group, patients on premix also showed
significantly greater hypoglycemic fear from week 12 to study end
(P<0.05).

The goal of the second study[2], conducted
with 220 type 1 and type 2 patients from 32 sites in Canada, was to
evaluate the change in diabetes treatment satisfaction in people
treated with insulin glargine. It showed that 96% of patients
experienced significant treatment satisfaction upon switching to
Lantus® SoloSTAR® from their previous
treatment: Diabetes Treatment Satisfaction Questionnaire at 6
months = 12.0 (SD = 5.4), compared to overall satisfaction at
baseline.

The objective of the third study,
LANSOLEAP[3], involving 143 adults with
either type 1 or type 2 diabetes in Mexico, was to evaluate
satisfaction with the SoloSTAR® insulin pen by adult patients. It
showed that:

83% rated SoloSTAR® as excellent

78% found SoloSTAR® easier to use overall, compared
with their previous device

87% preferred SoloSTAR® to their previous
device

Of those who had never used a pen device, 83% felt confident
about using SoloSTAR® on the same day they received the
pen.

Patient satisfaction is key to improving compliance, and
therefore treatment outcomes. As a patient-centric company focused
on the needs of people with diabetes Sanofi is committed to
improving treatment satisfaction and quality of life.

Notes to editors

About the studies

Polonskyet al (referred as the first
study) was a 60-week randomized, open-label study compared adding
BID premixed 70/30 insulin aspart (PREMIX), basal insulin glargine
+ 1 prandial insulin glulisine dose (GLARG+1), or stepwise addition
of prandial glulisine (GLARG+0-3) in 586 patients with uncontrolled
type 2 diabetes on oral agents. The objective was to evaluate any
within- and between-group changes in 1) physical and psychological
well-being, 2) diabetes-related symptoms, and 3) patient
satisfaction with diabetes-related care and treatment over the
study period and from baseline to endpoint. While achieving similar
glycemic control and body weight changes, GLARG+1 and GLARG+0-3
were more effective than PREMIX in FBG reduction and reaching A1C
<7%, while causing less overall hypoglycemia. Patient reported
outcomes were measured at baseline, 6, 12, 24, 36, 48, and 60 weeks
to assess overall quality of life, diabetes-specific quality of
life (DQoL), hypoglycemic fear and adjustment to illness.

Garonet al (referred as the second study)
evaluated the change in diabetes treatment satisfaction in 220
patients with type 1 or type 2 diabetes treated with
Lantus® SoloSTAR®. This 6-month
Canadian, observational, multicenter, prospective registry
collected data in 220 T1&T2 Diabetes patients from 32 sites
treated with any combination of unmixed basal insulin, oral
anti-hyperglycemic drugs or short-acting insulins who had
HbA1c > 7% or HbA1c ≤ 7% with
severe or frequent symptomatic hypoglycemia were enrolled in the
study. Treatment satisfaction was measured by using the standard
Diabetes Treatment Satisfaction Questionnaire at baseline (DTSQs)
and after 6 months (DTSQc). Patients acceptance of
SoloSTAR® pen was assessed using 8-item pen use
questionnaire having scores from 1=excellent to 5=very poor. 56
T1DM and 164 T2DM pts were on average 39.7 (SD=12.4) and 59.3
(SD=11.0) years old and had BMIs of 26.9 (SD=4.7) and 33.4 (SD=8.0)
kg/m2, respectively.

LANSOLEAP (referred as the third study) was a
multicenter, prospective, one-arm, six to eight week observational
study, involving adults with either type 1 or type 2 diabetes (who
were either insulin users, or insulin naïve and taking oral
medications and candidates for insulin therapy). The primary
objective was to evaluate satisfaction with SoloSTAR®,
evaluated by a self-assessment questionnaire pertaining to overall
acceptance (rating of SoloSTAR®) and ease and
continuation of use. In a second questionnaire, insulin users
assessed their preference for SoloSTAR® compared with
their previous device.

A total of 206 patients were enrolled, with 56 excluded for
failing to meet the minimum time of 30 days between visits. The
mean age of the 150 patients whose data could be analyzed was 53.3
years (range 18-90 yrs); 58.7% were female, 86.6% had type 2
diabetes, 68% had a BMI >25, and 70% had used insulin
previously. The 7 patients who did not inject insulin themselves
were excluded from the satisfaction evaluation.

About Lantus[®]

Lantus® (insulin glargine) is the first
24-hour once-daily basal insulin analog. Lantus®
is as effective as NPH insulin with similar reductions in
HbA1c, but is associated with lower fasting blood
glucose concentrations. People with Type 2 diabetes experience a
consistent and significant reduction in the incidence of nocturnal
hypoglycemia with
Lantus®.[4]

About Apidra[®]

Apidra® is a fast-acting insulin analog of human insulin with a
zinc-free molecular structure that maintains a rapid onset and a
short duration of action, indicated for the treatment of adults
with type 1 and type 2 diabetes. Apidra® offers mealtime
dosing flexibility − it can be taken 15 minutes before or within 20
minutes after starting a meal, and in a variety of body types, from
lean to obese.

About SoloSTAR®

SoloSTAR® is Sanofi's prefilled, multi-purpose,
disposable insulin pen for the administration of Lantus®,
Apidra® and Insuman®.
SoloSTAR[®]is the winner of a GOOD DESIGN™
Award.

About the Sanofi Diabetes Division

Sanofi strives to help people manage the complex challenges of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insight that comes from listening to
and engaging with people living with diabetes, the Company is
forming partnerships to offer diagnostics, therapies, services, and
devices. Sanofi markets both injectable and oral medications for
people with type 1 or type 2 diabetes. Investigational compounds in
the pipeline include an injectable GLP-1 agonist being studied as a
single agent, in combination with basal insulins, and/or in
combination with oral antidiabetic agents.

This press release contains
forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These
statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labeling and other
matters that could affect the availability or commercial potential
of such products candidates, the absence of guarantee that the
products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2010. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.

(Date:10/5/2017)... 2017 In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...

(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...

(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...

(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...

(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...

(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...